Clinical Trials Logo

Sleep Apnea, Obstructive clinical trials

View clinical trials related to Sleep Apnea, Obstructive.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05623709 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

Health Outcomes With CPAP or NIV in Patients With COPD and a Sleep Related Breathing Disorder

Start date: July 26, 2022
Phase:
Study type: Observational

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease affecting an estimated 1 in 10 Canadians. Symptoms include persistent shortness of breath, cough and sputum production. The symptoms can be serious when people with COPD experience a flare of their disease and may lead to hospitalization or death. Improving other conditions that affect COPD control is one way to improve the health of people with COPD. Obstructive sleep apnea (OSA) is the most common breathing problem during sleep, and commonly co-exists with COPD. Although diagnosing and treating OSA is encouraged, it has not been highlighted in guidelines that recommend ideal COPD care. People with COPD and OSA have lower sleep quality and lower oxygen levels during sleep compared to people with OSA. Despite these differences, treatment of OSA in people with COPD is modeled after treatment of OSA in the general population, generally using treatment with continuous positive airway pressure (CPAP) with the possible addition of oxygen through the CPAP machine. There are few studies looking at other types of treatment including noninvasive ventilation (NIV) in people with COPD and OSA. The majority of studies of NIV in COPD has been for people with other reasons to use NIV including acute respiratory failure or chronic hypercarbic respiratory failure and did not include people with risk factors for OSA or who had undergone overnight sleep studies. In Alberta, NIV is provided province wide for people who have both OSA who do not meet certain physiologic targets in their oxygen levels or breathing patterns after CPAP is applied on an overnight sleep study. NIV is provided preferentially to CPAP and oxygen, providing an opportunity to look at health outcomes when NIV is used instead of CPAP for the treatment of patients with COPD. Through this study, we will measure whether people with COPD and a sleep related breathing disorder such as OSA have fewer severe flares of COPD after starting CPAP or NIV. We will evaluate whether the number of Emergency Department visits, hospitalizations or deaths lowers after starting CPAP or NIV.

NCT ID: NCT05445869 Terminated - Clinical trials for Obstructive Sleep Apnea

Severe OSA Study (SOS)

Start date: September 12, 2022
Phase: N/A
Study type: Interventional

This study is a prospective, multi-center, single-arm, open-label study evaluating the safety and effectiveness of therapy with the ProSomnus EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea.

NCT ID: NCT05374941 Terminated - Clinical trials for Obstructive Sleep Apnea

StimAire Sleep Study

Start date: August 17, 2022
Phase: N/A
Study type: Interventional

The StimAire Model S is intended to treat Obstructive Sleep Apnea (OSA) by stimulating the hypoglossal nerve. The system includes a dedicated neurostimulator and a breathing sensor. The system is to be used in participants diagnosed with moderate to severe Obstructive Sleep Apnea. The Sponsor will be evaluating the change in Apnea-Hypopnea Index (AHI) when using the StimAire Model S system.

NCT ID: NCT05112757 Terminated - Atrial Fibrillation Clinical Trials

Effective Conversion of Individuals at Risk

Start date: February 24, 2022
Phase: N/A
Study type: Interventional

This study aims to guide participants in recognizing their OSA (obstructive sleep apnea) and AFib (atrial fibrillation) symptoms, realizing what medical conditions can cause these symptoms (if any) and inform the participants on their possible diagnosis

NCT ID: NCT04624815 Terminated - Asthma Clinical Trials

Factors Issued From Functional Exploration Associated to SAHOS in Asthmatic Children

SASTHMA
Start date: November 20, 2020
Phase:
Study type: Observational

There is an increase in the prevalence of obstructive apnea-hypopnea syndrome (OSA) in children for which the pathophysiological explanation is unknown. The main objective is to compare pharyngeal collapsibility in asthmatic children with SHS score > 2.75 or ≤ 2.75 (OSA prediction score validated in French). Secondary objectives: Compare pharyngeal size, tracheal size, loop gain and its components (controller, plant), lung volumes and expired and nasal NO in asthmatic children with SHS score > 2.75 or ≤ 2.75. The bias due to the possible existence of an alveolar hyperventilation syndrome associated with asthma will be taken into account.

NCT ID: NCT04530747 Terminated - Clinical trials for Sleep Apnea, Obstructive

Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea

MET-OSA
Start date: January 28, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to see if metformin improves metabolism in patients with obstructive sleep apnea (OSA) using positive airway pressure (PAP) therapy. Metformin is approved by the Food and Drug Administration (FDA) for the treatment and prevention of diabetes. It is not approved for use in patients with OSA.

NCT ID: NCT04425408 Terminated - Clinical trials for Positional Obstructive Sleep Apnea

Comparison of 2 Different Positional Therapies for Positional Obstructive Sleep Apnea Syndrome

Start date: February 1, 2020
Phase: N/A
Study type: Interventional

The proposed study is a randomized cross over trial assessing the efficacy of two different positional therapies for positional obstructive sleep apnea (POSA). The effectiveness of the two different therapeutic devices (Positional pillow and vibrating belt) in reducing the time spent sleeping supine, and therefore at risk of apnoeas, will be evaluated consecutively in 52 subjects with a de novo diagnosis of positional sleep apnoea. The subjective quality of sleep will also be evaluated prior to treatment and following the use of each separate device by means of a "Quality of sleep questionnaire"

NCT ID: NCT04211350 Terminated - Clinical trials for Obstructive Sleep Apnea

SLEEP ON Your SIDE (SOS) Study

SOS
Start date: February 4, 2019
Phase: N/A
Study type: Interventional

Comparison of the NightBalance Sleep Position Trainer (SPT) to Positive Airway Pressure (PAP) for the Treatment of Positional Obstructive Sleep Apnea (POSA). Primary Objective: Efficacy and Adherence of the SPT over 3 months of use compared to PAP for the treatment of POSA. The study is run from centers in France, the UK and Germany.

NCT ID: NCT04084990 Terminated - Clinical trials for Obstructive Sleep Apnea

Sleep Apnea and Fetal Growth Restriction

SAFER
Start date: November 18, 2019
Phase: Phase 3
Study type: Interventional

This study aims to evaluate the association between obstructive sleep apnea (OSA) and fetal growth restriction (FGR) and to assess the role of auto-titrated positive airway pressure (aPAP) as antenatal therapy in these patients. Pregnant patients with diagnosed FGR will be screened for OSA first by screening questionnaire and then by home sleep monitor. Of those patients diagnosed with OSA, half will be assigned to use aPAP each night when sleeping and half will not (standard care).

NCT ID: NCT04054180 Terminated - Clinical trials for Obstructive Sleep Apnea Syndrome

Multimodal Remote Monitoring and Integrated Educational Program in OSA Patients Initiating Continuous Positive Airway Pressure (CPAP): (SLEEPCONNECT)

SLEEPCONNECT
Start date: June 7, 2021
Phase: N/A
Study type: Interventional

Continuous positive airway pressure (CPAP) is the first line therapy for Obstructive Sleep Apnea Syndrome (OSAS) but has limited impact for reducing cardio-metabolic risk. Combined treatment strategies including physical activity and weight loss management have emerged in association with CPAP. Patient's engagement might be supported by connected devices and smartphone applications measuring physical activity, blood pressure, weight and sleep duration. Data fusion of these parameters with CPAP-remote telemonitoring will allow personalized coaching and integrated care of OSAS with cardio-metabolic co-morbidities.